Supriya Lifescience Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Supriya Lifescience Ltd filed with BSE on 18 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Supriya Lifescience reported Q1 FY'27 revenue of Rs. 190 crores, up 31% year-on-year, while EBITDA fell 8.1% to Rs. 47 crores with margins at 25%, which management attributed to a temporary water shortage near its Lote plant and a one-time solar power policy change. Management said around Rs. 35 crores of sales were deferred due to the water issue and Rs. 8 crores of EBITDA impact came from higher fuel and power costs. Management reiterated its target of approaching Rs. 1,000 crores in revenue for FY'27 and an EBITDA margin range of 33% to 35%, while discussing Ambernath facility launches, the Patalganga land project, and an ongoing customs matter involving an export authorization lapse.
Numbers mentioned
Revenue: Rs. 190 crores (Q1 FY'27)
p. 3
“Revenue for the quarter stood at Rs. 190 crores, reflecting a 31% year-on-year growth.”
Shivani Wagh, page 3 of the filed PDF · View the filing
EBITDA: Rs. 47 crores (Q1 FY'27)
p. 3
“During the quarter, EBITDA stood at Rs. 47 crores, a decline of 8.1% year-on-year with EBITDA margins at 25%.”
Shivani Wagh, page 3 of the filed PDF · View the filing
Revenue: Rs. 145 crores (Q1 FY'26)
p. 5
“For Q1 FY '27, the company reported revenue from operations of Rs. 190 crores as against Rs. 145 crores in Q1 FY '26, a growth of 31% year-on-year.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
EBITDA: Rs. 52 crores (Q1 FY'26)
p. 5
“EBITDA for the quarter stood at Rs. 47 crores as against Rs. 52 crores in Q1 FY '26, a degrowth of 8.1% year-on-year and EBITDA margin stood at 25% for Q1 FY '27.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
PAT: Rs. 24 crores (Q1 FY'27)
p. 5
“PAT stood at Rs. 24 crores as against Rs. 35 crores in Q1 FY '26.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
PAT margin: 12.7% (Q1 FY'27)
p. 5
“PAT margins stood at 12.7% for Q1 FY '27.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
CapEx: Rs. 16.58 crores (Q1 FY'27)
p. 5
“Our CapEx for Q1 FY ’27 stood at Rs. 16.58 crores driven by spend on maintenance CapEx, smaller projects, formulation plan requirements and Isambe project.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
Export contribution to revenue: 81% (Q1 FY'27)
p. 4
“Exports continued to be a key growth driver contributing 81% of revenue in Q1 FY '27.”
Shivani Wagh, page 4 of the filed PDF · View the filing
Backward integration of revenue: 72% (Q1 FY'27)
p. 4
“Our core strategy for backward integration continued to progress and currently we have 72% of total revenues fully integrated.”
Shivani Wagh, page 4 of the filed PDF · View the filing
Solar power retrospective cost impact: Rs. 4.5 crores - Rs. 5 crores (Q1 FY'27)
p. 7
“See, this would be somewhere around Rs. 4.5 crores - Rs. 5 crores at this stage.”
Krishna Raghunathan, page 7 of the filed PDF · View the filing
Cash reserves: Rs. 150 crores
p. 18
“See, we have around Rs. 150 crores in FDs and mutual funds.”
Krishna Raghunathan, page 18 of the filed PDF · View the filing
Closing inventory: Rs. 230 crores to Rs. 240 crores (as of June 30)
p. 10
“Somewhere around Rs. 230 crores to Rs. 240 crores. It is on the higher side.”
Krishna Raghunathan, page 10 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue — Rs. 1,000 crores · FY '27
stated firmly by Shivani Wagh
p. 4
“we would like to reiterate that our trajectory towards the Rs. 1,000 crores revenue by FY '27 remains firmly on track, supported by a robust product pipeline and a sustained demand across key therapeutic segments including anesthetics, anti-diabetics, anti-anxiety, vitamins, and ADHD.”
Shivani Wagh, page 4 of the filed PDF · View the filing
EBITDA margin — 33% to 35% · FY '27
stated firmly by Shivani Wagh
p. 4
“We remain confident of our guidance of EBITDA margins in the range of 33% to 35%.”
Shivani Wagh, page 4 of the filed PDF · View the filing
Contrast media product launch — H2 FY '27
stated firmly by Shivani Wagh
p. 4
“We expect the products to be launched in H2 FY '27.”
Shivani Wagh, page 4 of the filed PDF · View the filing
EU audit at Ambernath — second half of November
stated firmly by Dr. Saloni Wagh
p. 6
“The audit is scheduled for the second half of November.”
Dr. Saloni Wagh, page 6 of the filed PDF · View the filing
Revenue growth CAGR — 20% year-on-year · beyond FY '27
stated as an aspiration by Dr. Saloni Wagh
p. 13
“we have already said that we would be growing at a CAGR of about 20% year-on-year. I think the same trend would continue.”
Dr. Saloni Wagh, page 13 of the filed PDF · View the filing
ATS-8 product volume — 250 metric tons · next two years
stated conditionally by Dr. Saloni Wagh
p. 14
“So, we had said that the 250 metric ton number will be achieved in the next two years' time once it is fully commercialized.”
Dr. Saloni Wagh, page 14 of the filed PDF · View the filing
Depreciation — Rs. 35 crores to Rs. 40 crores · full year
stated firmly by Krishna Raghunathan
p. 10
“So, that you can add up to a regular I think should be somewhere around nearing to Rs. 35 crores to Rs. 40 crores should be the overall depreciation.”
Krishna Raghunathan, page 10 of the filed PDF · View the filing
EBITDA margin — 33% to 35% · next three to four years
stated as an aspiration by Dr. Saloni Wagh
p. 19
“So, I think the margins would remain at that 33% to 35% at least for the next three to four years.”
Dr. Saloni Wagh, page 19 of the filed PDF · View the filing
Block F construction start — next couple of quarters
stated firmly by Krishna Raghunathan
p. 11
“We will be starting it in next couple of quarters.”
Krishna Raghunathan, page 11 of the filed PDF · View the filing
SAP implementation go-live — another four to five months
stated firmly by Dr. Saloni Wagh
p. 15
“As we speak, we are actually under SAP implementation, so we will be live in another four to five months, we should be live with our SAP, which will further strengthen our internal system.”
Dr. Saloni Wagh, page 15 of the filed PDF · View the filing
Patalganga Phase-1 CapEx — Rs. 200 crores · Phase-1
stated firmly by Krishna Raghunathan
p. 5
“The total CapEx earmarked for this facility is around Rs. 200 crores for Phase-1.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said boundary wall construction has already begun, effectively breaking ground.
Answered by Krishna Raghunathan
Asked by Adityapal: Why is there a delay in breaking ground and starting construction at Patalganga?
p. 5
“So, technically, we have broken the ground.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
Management said the retrospective portion was one-time but ongoing price increases would be passed to customers.
Answered by Krishna Raghunathan
Asked by Nikhil: Is the solar power cost increase a one-time item or will it recur?
p. 6
“See, there are two things on solar subsidy. I think the government is asking even to pay from July 25.”
Krishna Raghunathan, page 6 of the filed PDF · View the filing
Management said R&D is still fine-tuning technology and process amid raw material cost variations.
Answered by Dr. Saloni Wagh
Asked by Nikhil: Why was the contrast media launch delayed?
p. 7
“Also, I think our biggest issue why the launch has been delayed by two quarters is because the R&D is still fine-tuning on the technology part of it because there have been multiple variations in the cost of the raw material.”
Dr. Saloni Wagh, page 7 of the filed PDF · View the filing
Management reaffirmed confidence in reaching close to Rs 1,000 crores revenue and 32-35% EBITDA margin.
Answered by Dr. Saloni Wagh
Asked by Mulesh: Is annual guidance on revenue and margins still intact given cost pressures?
p. 9
“Now as regards the guidance, we are still confident that we will be able to make up for this lost Rs. 25 crores - Rs. 30 crores of sales in the coming few quarters.”
Dr. Saloni Wagh, page 9 of the filed PDF · View the filing
Management said no provision was needed since a new export authorization was received.
Answered by Krishna Raghunathan
Asked by Mulesh: Was any provision made against the sales tied to the customs/export authorization matter?
p. 9
“At this point of time, like my MD has already said, we had already got the re-export permit from Central Bureau of Narcotics.”
Krishna Raghunathan, page 9 of the filed PDF · View the filing
Management said it was a two-day technical lapse due to human oversight in logistics, not a document deficiency.
Answered by Dr. Saloni Wagh
Asked by Mulesh: How did the export authorization lapse occur?
p. 9
“There was only a technical lapse of two days where there was a human oversight by the logistics department and that the given export authorization had expired before the shipping bill was raised.”
Dr. Saloni Wagh, page 9 of the filed PDF · View the filing
Management confirmed the individual remains in judicial custody as the matter is sub judice.
Answered by Dr. Saloni Wagh
Asked by Abhishek: What is the status of the general manager implicated in the matter?
p. 10
“No. Like I mentioned, the matter is still sub judice. So, they are still in judicial custody.”
Dr. Saloni Wagh, page 10 of the filed PDF · View the filing
Management said they are close to signing a term sheet for a large anesthetic CDMO contract.
Answered by Dr. Saloni Wagh
Asked by Nirmam Mehta: Any updates on CMO contracts under discussion?
p. 10
“We are very close to signing a term sheet.”
Dr. Saloni Wagh, page 10 of the filed PDF · View the filing
Management attributed it to multiple DMF filings and customers ramping validation volumes.
Answered by Dr. Saloni Wagh
Asked by Rachna Kukreja: What drove sequential improvement in North America and will it continue?
p. 11
“Specifically, we have filed at least four to five US DMFs and a lot of the customers have now started picking up the volumes for their validation and everything.”
Dr. Saloni Wagh, page 11 of the filed PDF · View the filing
Management said it was a mix of factors including lower European sales and production losses affecting regulated market materials.
Answered by Krishna Raghunathan
Asked by Rachna Kukreja: Why did revenue mix from backward integrated products decline and impact margins?
p. 12
“Multiple factors, I could say. If you would follow the script, what my Joint MD had suggested, see there were some production losses and because of which certain of the materials which were supposed to go into regulated markets could not go.”
Krishna Raghunathan, page 12 of the filed PDF · View the filing
Management said the large shutdown has been pushed back and replaced with smaller debottlenecking activities.
Answered by Dr. Saloni Wagh
Asked by Saloni Singh: What is the impact of the planned Q2 shutdown on revenue?
p. 13
“So, the planned shutdown will not happen in Quarter 2 anymore.”
Dr. Saloni Wagh, page 13 of the filed PDF · View the filing
Management confirmed a stronger second half and said growth beyond 20% is possible depending on regulatory approvals.
Answered by Dr. Saloni Wagh
Asked by Tushar Bohra: Is a stronger second-half ramp-up expected and is growth beyond 20% possible?
p. 15
“So, keeping in mind the different areas in which the management is working, there is definitely potential in the business to grow beyond that 20% as well.”
Dr. Saloni Wagh, page 15 of the filed PDF · View the filing
Management said current exposure to North America is limited and Europe remains the larger market.
Answered by Dr. Saloni Wagh
Asked by Mithin Shah: How exposed is the company to US tariffs on pharma products given North America contribution?
p. 18
“And also having said that, I think our exposure is mainly larger at this point in Europe and even for the finished formulations, the larger opportunities for us are coming from Europe.”
Dr. Saloni Wagh, page 18 of the filed PDF · View the filing
Management said margins are expected to remain in the current range for the next few years.
Answered by Dr. Saloni Wagh
Asked by Aanchal Maheshwari: Will margins improve further as the formulation business grows?
p. 19
“No, I think the margins would remain where we are today, mainly because there we are looking at CMO, CDMO kind of opportunities.”
Dr. Saloni Wagh, page 19 of the filed PDF · View the filing
Risks flagged
Water shortage near Lote plant delayed sales
p. 3
“the entire Lote MIDC industrial belt faced a significant water shortage. This led to delay in sales as highlighted earlier.”
Shivani Wagh, page 3 of the filed PDF · View the filing
Maharashtra solar power policy change increased fuel and power costs
p. 3
“Second, Maharashtra government changed the solar power policy, which led to increased fuel and power costs during the quarter. This alone had an impact of Rs. 8 crores at EBITDA levels.”
Shivani Wagh, page 3 of the filed PDF · View the filing
Non-linear growth expected across quarters
p. 4
“However, as highlighted in our earlier call, growth is expected to be non-linear across quarters.”
Shivani Wagh, page 4 of the filed PDF · View the filing
Export shipment under investigation due to expired export authorization
p. 8
“So, currently, the matter is still sub judice.”
Dr. Saloni Wagh, page 8 of the filed PDF · View the filing
Potential future US tariffs on pharma products
p. 18
“See, as of now, I think after a couple of years, I think there is going to be a 100% tariff on pharma.”
Krishna Raghunathan, page 18 of the filed PDF · View the filing
Contrast media launch delayed due to raw material cost variations and process fine-tuning
p. 7
“there have been multiple variations in the cost of the raw material.”
Dr. Saloni Wagh, page 7 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.